Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2024, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.09 billion, up 7.5% over the same period last year. EPS came in at $6.60, compared to $5.02 in the year-ago quarter.The reported revenue represents a surprise of +2.57% over the Zacks Consensus Estimate of $1.06 billion. With the consensus EPS estimate being $5.79, the EPS surprise was +13.99%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net: $1.03 billion versus the 10-analyst average estimate of $995.17 million. The reported number represents a year-over-year change of +6%. Total revenues- Oncology- Defitelio/defibrotide: $57.65 million versus the nine-analyst average estimate of $46.52 million. The reported number represents a year-over-year change of +12.9%. Total revenues- Neuroscience- Oxybate- Xywav: $400.96 million versus the nine-analyst average estimate of $393.28 million. The reported number represents a year-over-year change of +19%. Total revenues- Neuroscience- Epidiolex/Epidyolex: $275.05 million compared to the $264.59 million average estimate based on nine analysts. The reported number represents a change of +14.3% year over year. Total revenues- Neuroscience- Sativex: $5.17 million versus $6.58 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change. Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $450.25 million versus the nine-analyst average estimate of $443.06 million. The reported number represents a year-over-year change of +1.5%. Total revenues- Neuroscience- Total: $730.47 million versus the nine-analyst average estimate of $714.23 million. The reported number represents a year-over-year change of +5.9%. Total revenues- Oncology- Total: $291.76 million versus the nine-analyst average estimate of $276.22 million. The reported number represents a year-over-year change of +6.6%. Total revenues- Oncology- Rylaze: $101.49 million versus the nine-analyst average estimate of $99.81 million. The reported number represents a year-over-year change of -0.3%. Total revenues- Oncology- Vyxeos: $53.25 million versus the nine-analyst average estimate of $42.05 million. The reported number represents a year-over-year change of +13.5%. Total revenues- Oncology- Zepzelca: $78.33 million versus the nine-analyst average estimate of $91.31 million. The reported number represents a year-over-year change of +5.8%. Total revenues- Other: $2.97 million versus $3.84 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -27.3% change. View all Key Company Metrics for Jazz here>>>Shares of Jazz have returned +9.9% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks